Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Akansha Chowdhary"'
Autor:
Mudit Chowdhary, MD, Neilayan Sen, MD, Akansha Chowdhary, MD, Lydia Usha, MD, Melody A. Cobleigh, MD, Dian Wang, MD, PhD, Kirtesh R. Patel, MD, Parul N. Barry, MD, Ruta D. Rao, MD
Publikováno v:
Advances in Radiation Oncology, Vol 4, Iss 3, Pp 453-457 (2019)
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however,
Externí odkaz:
https://doaj.org/article/687ff5b0e4af43e08117257c105f29a6
Autor:
J. Randall Patrinely, Ben McGuigan, Sunandana Chandra, Sarah E. Fenton, Akansha Chowdhary, Lucy B. Kennedy, Meghan J. Mooradian, Marisa Palmeri, Daniella Portal, Sara N. Horst, Elizabeth A. Scoville, Georgina V. Long, Chanjuan Shi, Janice M. Mehnert, Ryan J. Sullivan, April K. Salama, Jeffrey A. Sosman, Alexander M. Menzies, Douglas B. Johnson
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective study, patients from six
Externí odkaz:
https://doaj.org/article/de26ed8c2f814f73ad812c4ee03fc68d
Autor:
Kristina Navrazhina, Kelly Abbate, Barbara Durden, Song Park, Akansha Chowdhary, Jonathan Kennedy, Jessica Yang, Daniel Manson, John M Kirkwood, Alexander Shoushtari
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Uveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and safety of dual checkpoint blockade with nivolumab and ipilimumab is not wel
Externí odkaz:
https://doaj.org/article/af78c8c4442f42e39c146dd7aedcf3ad
Autor:
Kirtesh R. Patel, Dian Wang, Mudit Chowdhary, Nicholas G. Zaorsky, Akansha Chowdhary, Neilayan Sen
Publikováno v:
Cancer. 125:3801-3809
BACKGROUND The role of chemotherapy in extremity/trunk soft-tissue sarcoma (ET-STS) is controversial, even for patients at high risk for distant recurrence and death (those with high-grade tumors ≥5 cm in size). This study examines the impact of in
Autor:
Alexander M. Menzies, Melinda E. Sanders, Yan Liang, Elizabeth I. Buchbinder, Simon Mallal, Cody A. Chastain, Yu Wang, Akansha Chowdhary, Elisabeth J. Rushing, Daniel Y. Wang, Chanjuan Shi, Joseph M. Beechem, Meabh O'Hare, Bret C. Mobley, Amanda C. Guidon, Jeffrey A. Sosman, Justin M. Balko, Paula I. Gonzalez-Ericsson, Sarah Warren, Justine V. Cohen, Sunandana Chandra, Joe-Elie Salem, Javid Moslehi, Martin Tio, Kristi Barker, Simone M. Goldinger, Yaomin Xu, Douglas B. Johnson, Bénédicte Lebrun-Vignes, Rami N. Al-Rohil, Violeta Sanchez, Wyatt J. McDonnell, Georgina V. Long
Publikováno v:
Nature Medicine. 25:1243-1250
Checkpoint inhibitors produce durable responses in numerous metastatic cancers, but immune-related adverse events (irAEs) complicate and limit their benefit. IrAEs can affect organ systems idiosyncratically; presentations range from mild and self-lim
Autor:
Kirtesh R. Patel, Mudit Chowdhary, Akansha Chowdhary, Neilayan Sen, Ruta D. Rao, Parul N. Barry, Melody A. Cobleigh, Dian Wang, Lydia Usha
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 4, Iss 3, Pp 453-457 (2019)
Advances in Radiation Oncology, Vol 4, Iss 3, Pp 453-457 (2019)
Purpose Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, t
Autor:
Akansha Chowdhary, Mudit Chowdhary, Ruta D. Rao, Melody A. Cobleigh, Neilayan Sen, Demin Wang, Lydia Usha, Parul N. Barry, Kirtesh R. Patel
Publikováno v:
Cancer Research. 79:PD8-12
Purpose: Palbociclib is a selective CDK4/6 inhibitor approved for the treatment of metastatic ER+/HER2- breast cancer. Inhibition of CDK4/6 prevents cell cycle progression from G1 to the more radioresistant S phase, raising the possibility of an enha
Autor:
K. Patel, Gavin P. Jones, Narjust Duma, Mudit Chowdhary, Akansha Chowdhary, Miriam A. Knoll, Curtiland Deville, N. Dhawan, Trevor J. Royce, Arpit M. Chhabra, Neha Vapiwala, Karen M. Winkfield
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e335-e336
Purpose/Objective(s) Gender & racial/ethnic leadership disparities have been independently identified in academic hematology/oncology (HO) and radiation oncology (RO). Here, we evaluate gender and racial/ethnic intersectionality from the trainee to t
Autor:
Sarah E. Fenton, April K.S. Salama, Sunandana Chandra, Lucy Boyce Kennedy, Georgina V. Long, Akansha Chowdhary, Chanjuan Shi, Daniella E Portal, J. Randall Patrinely, Sara N. Horst, Marisa Palmeri, Janice M. Mehnert, Alexander M. Menzies, Douglas B. Johnson, Meghan J. Mooradian, Jeffrey A. Sosman, Elizabeth A. Scoville, Ryan J. Sullivan, Ben McGuigan
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective study, patients from six
Autor:
Roma Bhatia, Alexander N. Shoushtari, Kristina Navrazhina, Jonathan Kennedy, Katy K. Tsai, Fei Ding, John M. Kirkwood, Pankit Vachhani, Ryan J. Sullivan, Justine V. Cohen, Yana G. Najjar, Akansha Chowdhary, Tan Xu, Douglas B. Johnson, Igor Puzanov, Zeynep Eroglu, Shailender Bhatia, Richard D. Carvajal, Barbara Durden, Kelly Abbate, Pauline Funchain, Jessica Yang, Song Park, Marc S. Ernstoff, Joseph J. Drabick, Sunandana Chandra, Arun D. Singh, Daniel K. Manson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundUveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and safety of dual checkpoint blockade with nivolumab and ipilimumab is not well